| Quinolones: a comprehensive review CM Oliphant, GM Green American family physician 65 (3), 455-465, 2002 | 816 | 2002 |
| Antibiotic resistance, part 2: gram-negative pathogens CM Oliphant, K Eroschenko The Journal for Nurse Practitioners 11 (1), 79-86, 2015 | 40 | 2015 |
| Enhancing pharmacy faculty well-being and productivity while reducing burnout DR Kennedy, P Clapp, JL DeLuca, TM Filtz, L Kroon, JT Lamberts, ... American Journal of Pharmaceutical Education 86 (5), 8764, 2022 | 39 | 2022 |
| Efficacy of oral β-lactam versus non-β-lactam treatment of uncomplicated cellulitis KJ Madaras-Kelly, RE Remington, CM Oliphant, KL Sloan, DT Bearden The American journal of medicine 121 (5), 419-425, 2008 | 35 | 2008 |
| Antibiotic resistance, part 1: gram-positive pathogens CM Oliphant, K Eroschenko The Journal for Nurse Practitioners 11 (1), 70-78, 2015 | 33 | 2015 |
| Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens MH Scheetz, KM Hurt, GA Noskin, CM Oliphant American journal of health-system pharmacy 63 (14), 1346-1360, 2006 | 29 | 2006 |
| A descriptive study of factors associated with teacher identification of gifted students CC Oliphant Temple University, 1985 | 22 | 1985 |
| Naloxone: An opportunity for another chance T Calás, M Wilkin, CM Oliphant The Journal for Nurse Practitioners 12 (3), 154-160, 2016 | 14 | 2016 |
| Factors contributing to vaccine hesitancy and reduced vaccine confidence in rural underserved populations R Robinson, E Nguyen, M Wright, J Holmes, C Oliphant, K Cleveland, ... Humanities and Social Sciences Communications 9 (1), 1-8, 2022 | 13 | 2022 |
| Antimicrobial regimen selection CM Oliphant, K Madaras-Kelly Dipiro JT, 7th edition, United States: The McGraw-Hill Companies, Inc, 2008 | 11 | 2008 |
| Understanding COVID-19 vaccine hesitancy among students in health professions: A cross-sectional analysis CE Bonnema, I van Woerden, JR Steinberg, E Nguyen, CM Oliphant, ... Journal of Allied Health 50 (4), 314-320, 2021 | 10 | 2021 |
| Pentamidine-induced torsades de pointes LAF Zanetti, CM Oliphant Annals of Pharmacotherapy 28 (2), 282-283, 1994 | 4 | 1994 |
| Influences, barriers, and facilitators to COVID-19 Vaccination: cross-sectional survey on Vaccine Hesitancy in 2 Rural States E Nguyen, M Wright, J Holmes, K Cleveland, C Oliphant, M Nies, ... JMIR Formative Research 6 (12), e39109, 2022 | 3 | 2022 |
| Management of orthopedic infections CM Oliphant The Journal for Nurse Practitioners 11 (10), 1036-1042, 2015 | 2 | 2015 |
| FEATURES-Pharmacist-Physician-Patient Relationships-Management of Urinary Incontinence ME DeBisschop, CM Oliphant US Pharmacist 27 (2), 51-59, 2002 | 2 | 2002 |
| New advances in the pharmacological treatment of human immunodeficiency virus (HIV) infection: focus on protease inhibitors CM Oliphant, SM Bonnema Journal of Pharmacy Practice 10 (1), 20-51, 1997 | 2 | 1997 |
| Responsibility for ethical prescribing A Mitchell, CM Oliphant The Journal for Nurse Practitioners 12 (3), A20, 2016 | 1 | 2016 |
| New Antimicrobial Agents CM Oliphant The Journal for Nurse Practitioners 12 (3), e91-e100, 2016 | 1 | 2016 |
| Current Issues in Gram-Negative Resistance: Mechanisms and Treatment of Resistant Gram-Negative Pathogens CM Oliphant, M Scheetz ADVANCES IN PHARMACY 3 (2), 119, 2005 | 1 | 2005 |
| FEATURES-Pharmacist-Patient-Provider Relationships-Medication Use and Falls in Elderly Patients M DeBisschop, CM Oliphant US Pharmacist 24 (11), 98-103, 1999 | 1 | 1999 |
